PRESS

On-Demand Industry Programs

HomeProgramIndustry Programs ▶ On-Demand Industry Programs

Enhance your educational experience on the ATS 2022: On-demand Highlights by listening to industry experts discuss on the latest information on products/services or disease awareness related to pulmonary, critical care, and sleep medicine.

Programs are available on-demand through June 24. To access the industry program, click on the title of the program below to be directed to ATS 2022: On-demand Highlights. The platform is only accessible by registered attendees.

icons-industry-programs11162021-webinar.svg


Available On-Demand: May 25 - June 24

Looking Into the “I”s of NCFB


Non-cystic fibrosis bronchiectasis (NCFB) results from an initial airway Injury that leads to a cycle of Inflammation, airway remodeling, Increased mucus production, and repeated Infection. Pulmonary exacerbations lead to irreversible disease progression, reduced quality of life, and increased morbidity and mortality. Due to the disease heterogeneity and the absence of standardized definitions, NCFB is often misdiagnosed or underdiagnosed. The lack of approved therapies and the rising prevalence of NCFB underscores the importance of expanding disease awareness and developing effective treatment. This webinar will discuss the current landscape of NCFB pathophysiology, diagnosis, treatment strategies, and future directions.

Speakers: Stefano Aliberti MD Humanitas Research Hospital, Milan, Italy ; Charles Haworth MD, FRCP Royal Papworth Hospital NHS Foundation Trust, Cambridge, England ; Kevin Winthrop MD, MPH Oregon Health and Science University, Portland, Oregon

Company: Zambon USA Ltd.

Moving Beyond Misperceptions of Asthma Control and Stepping Towards Personalized Care (Open to U.S. attendees only)


This program will focus on the recognition and the management of uncontrolled asthma, as well as understanding the burden and subsequent challenges faced by patients and healthcare providers. Beginning with acknowledging and understanding the common misperceptions in assessing control, this program will explore the pathophysiology and heterogeneity of asthma and provide evidence-based insight on ways to personalize patient care through the application of clinical and guidelines-based management.

Speakers: Priya Bansal Asthma and Allergy Wellness Center; an Carlos Cardet MD, MPH University of South Florida

Company: GSK

Spotting the Zebra: EGPA and HES Case-Based Learning (Open to U.S. attendees only)


Eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES) are rare eosinophilic disorders that present similarly and thus present a diagnostic challenge. Join an expert allergist-immunologist for an interactive, case-based discussion that will highlight the role of multidisciplinary collaboration in facilitating and expediting the diagnosis and management of these heterogeneous disease states. 

Speaker: Mili Shum MD University of Utah Health

Company: GSK

Targeting signaling pathways implicated in PAH vascular remodeling: a bridge to new therapeutic options


Please join Drs Sahay, Sood, and Zisman for a discussion about new understandings of the underlying pathophysiology of PAH. The panelists will be discussing the pathways responsible for the inflammation, proliferation, and fibrosis that leads to the narrowing and thickening of the lung vasculature in PAH. The audience will also learn about ongoing clinical research programs exploring new therapeutic interventions, as well as new approaches to bridging research and clinical practice in PAH.

Speakers: Namita Sood MD, FCCP University of California, Davis; Sandeep Sahay MD, FCCP Houston Methodist; Larry Zisman MD Gossamer Bio

Company: Gossamer Bio

What’s Your Type? Solving Clinical Dilemmas of Persistent Severe Asthma Through Endophenotyping (Open to U.S. attendees only)


Join our expert as he leads an interactive discussion on the clinical challenges presented by severe, uncontrolled asthma. An interactive patient case will explore the pathophysiology and clinical presentation of severe asthma, its comorbidities and the burden of OCS associated with them. We will review the importance of endophenotyping and evaluating for T2 inflammation, as well as highlight strategies to reduce OCS use in these patients.

Speaker: Jonathan Corren MD

Company: GSK